Marinus pushes on despite mid-stage doubts
The group’s determination to conquer another rare epilepsy, tuberous sclerosis complex, looks questionable.
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
Quiet times return for biopharma takeouts
The first quarter of 2021 saw fewer deals than any in recent memory.
Fresh antitrust push hits biopharma
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
2020 wins top of the froths for biotech stocks
It's official: dramatic share price jumps in response to clinical data have become more common.
